Pharmacyclics Inc. (NASDAQ: PCYC) has seen its stock surge in the past week as rumors swirl about a potential acquisition. News finally broke late Wednesday that there was an official buyout in the works by AbbVie Inc. (NYSE: ABBV) for $21 billion.
Note that this is AbbVie’s first major deal attempt since last fall, when it attempted a takeover of Shire PLC (NASDAQ: SHPG) for $55 billion.
Some analysts saw this coming and issued calls leading up to the announcement. Others are just reacting to it. 24/7 Wall St. has included information from the Credit Suisse report and tagged a few other calls that have been made.
Credit Suisse detailed that it likes AbbVie’s diversification strategy, which it indicated in its “surprising” $21 billion acquisition of Pharmacyclics and its blood-cancer drug Imbruvica. However, the brokerage firm is bearish on the price.
It is not hard to be bearish on the price, considering Pharmacyclics shares have increased 88.5% year-to-date. Looking back even further, this was just a $10 stock in 2011.
The investment bank calls the deal size “manageable” and possibly “highly accretive” by 2017. But the price, given Pharmacyclics’ 50-50 profit split with Johnson & Johnson (NYSE: JNJ) on Imbruvica, “seems to imply some degree of success for Imbruvica in other indications where there is limited human clinical data.”
ALSO READ: The 5 Most Loved Biotech Stocks of Portfolio Managers
In the week leading up to the announcement, these analysts made calls when the buyout was only suspected:
- WallachBeth Capital downgraded shares to Hold from Buy on February 26.
- Goldman Sachs downgraded Pharmacyclics to Neutral from Buy on February 27.
- Wedbush downgraded shares to Neutral from Outperform with a price target of $234, up from $225, on March 3.
A couple of analysts weighed in after the announcement:
- BTIG Research downgraded Pharmacyclics to Neutral from Buy.
- RBC Capital maintained a Sector Perform rating and raised its price target to $261 from $145.
Shares of Pharmacyclics were up about 10.6% at $254.84 Thursday morning. The stock has a consensus analyst price target of $196.95 and a 52-week trading range of $82.51 to $255.52.
It’s Your Money, Your Future—Own It (sponsor)
Retirement can be daunting, but it doesn’t need to be.
Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter!
Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.